Day: March 13, 2023

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

OV329 Phase 1 trial is progressing on track An IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator portfolio Takeda’s guidance on soticlestat remains unchanged; anticipates regulatory filings in its FY 2024 Current cash runway expected to fund operations into the first half of 2025NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. “Ovid has significant momentum entering 2023. OV329, our next generation GABA-aminotransferase inhibitor...

Erdene Announces 2022 Results and Provides Khundii Minerals District Update

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

HALIFAX, Nova Scotia, March 13, 2023 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the year ended December 31, 2022, and to provide an update on its Khundii Minerals District (“KMD”), including its Bayan Khundii Gold Project (“Bayan Khundii” or “BK”). This release should be read in conjunction with the Company’s 2022 Financial Statements and MD&A, available on the Company’s website and SEDAR. Quotes from the Company: “Our 2022 exploration program successfully expanded resources in the Khundii Minerals District, while our technical team prepared the Bayan Khundii Gold Project for development,” said Peter Akerley, Erdene’s President and CEO. “Drilling during the year at our Dark Horse Mane...

MariMed Announces Close on Acquisition of Ermont, Inc. Operating Assets

Written by Customer Service on March 13, 2023. Posted in Mergers And Acquisitions.

NORWOOD, Mass., March 13, 2023 (GLOBE NEWSWIRE) — MariMed, Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator, and Ermont Inc. (“Ermont”) a vertically integrated medical cannabis operator located in Quincy, MA, today announced the close of MariMed’s transaction to acquire the operating assets of Ermont. The deal was previously announced on February 21, 2023. The acquisition marks the second medical dispensary for MariMed in Massachusetts, substantially completing the Company’s buildout to the maximum allowable by state regulations. The transaction closed on March 9, 2023, and the dispensary began operations under the Panacea Wellness brand name the following day. The dispensary now features an expanded selection of the best cannabis products produced in the state, including those...

Automotive Adhesives Market worth $9.3 billion in 2026 Globally, at a CAGR of 5.9%, says MarketsandMarkets™

Written by Customer Service on March 13, 2023. Posted in Mergers And Acquisitions.

Chicago, March 13, 2023 (GLOBE NEWSWIRE) — The global Automotive Adhesives Market was valued at USD 6.6 billion in 2020 and is projected to reach USD 9.3 billion by 2026, growing at a CAGR 5.9% from 2021 to 2026, as per the recent study by MarketsandMarkets™. The growing trend for lightweight and low carbon-emitting vehicles and the high demand for automotive adhesives from APAC are the drivers in the market. The major growth opportunities in the automotive adhesives market are in India, China, Brazil, Mexico, and other emerging economies. Automotive adhesives improve the aesthetic appeal of end products as bolts, rivets, and welds are not required to be used, and thus making these viable for numerous applications involving assembly line, body in white, and others. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36961165 Browse...

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Plan to commence Phase 1b/2 clinical trial in US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the second quarter of 2023 after receipt of FDA clearance for Investigational New Drug (IND) application in January 2023 On track to commence Phase 1/2 clinical trial in China evaluating FasTCAR-T GC012F in RRMM in the third quarter 2023 following receipt of NMPA clearance for IND application in February 2023 Continuing patient enrollment and follow-up in the ongoing IIT evaluating FasTCAR-T GC012F in relapsed/refractory B-Cell non-Hodgkin lymphoma (r/r B-NHL) On track to commence a China IIT for SMART CAR-T GC506 in Claudin18.2-positive solid tumors in first half of 2023 Well-funded with cash runway to the end of 2024 Management to host conference call at 8:00 a.m. ET todaySAN DIEGO and...

Whole Earth Brands Reports Fourth Quarter and Full Year 2022 Results and Provides 2023 Guidance

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Reported fourth quarter revenue growth of 4.7%; constant currency revenue growth of 7.0% reflecting strong performance across both segments CHICAGO, March 13, 2023 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company” or “we” or “our”) (Nasdaq: FREE), a global food company enabling healthier lifestyles through premium plant-based sweeteners, flavor enhancers and other foods, today announced its financial results for its fourth quarter and full year ended December 31, 2022. The Company also provided 2023 guidance. Full Year HighlightsReported consolidated revenue growth of 9.0%, including a full year of the Wholesome acquisition compared to approximately 11 months in the prior year. Constant currency consolidated revenue grew 11.6% Pro forma organic constant currency consolidated revenue grew 7.1%, driven by a 6.4% increase...

Applied Materials Increases Cash Dividend by 23.1 Percent and Announces New $10 Billion Share Repurchase Authorization

Written by Customer Service on March 13, 2023. Posted in Dividend Reports And Estimates.

SANTA CLARA, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced that its Board of Directors has approved a 23.1-percent increase in the quarterly cash dividend from $0.26 to $0.32 per share. The dividend is payable on June 15, 2023 to shareholders of record as of May 25, 2023. The Board also approved a new share repurchase authorization enabling Applied to buyback an additional $10 billion of its shares over time. This supplements the previous authorization which had $4.7 billion remaining at the end of the first quarter of fiscal 2023. “The dividend increase, our largest in five years, and the new share repurchase authorization reflect our positive long-term view of the semiconductor market and our confidence in Applied’s outsized growth opportunities driven by our technology leadership, broad portfolio...

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Interim Analysis of Registration-Enabling Phase 3 Fibromyalgia Trial of TNX-102 SL Expected Second Quarter 2023; Topline Data Expected Fourth Quarter 2023 Potentially Pivotal Phase 2 Trials of TNX-1900 in Chronic Migraine and TNX-601 ER in Depression Scheduled for Interim Analyses in Fourth Quarter 2023 Potentially Pivotal Phase 2 Fibromyalgia-Type Long COVID Study Enrolling Cash and Cash Equivalents Totaled Approximately $120.2 Million at December 31, 2022 CHATHAM, N.J., March 13, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an overview of recent operational highlights. “Our clinical activity is at a high point in the Company’s...

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Written by Customer Service on March 13, 2023. Posted in Earnings Releases And Operating Results.

Amyotrophic lateral sclerosis (ALS): Significant survival benefits demonstrated across two ALS clinical trials, along with clinical improvements as early as six monthsCNM-Au8® associated with 74% lower risk of ALS clinical worsening events at six months supporting a survival benefit in the HEALEY ALS Platform Trial CNM-Au8 significantly preserved physical function (ALSFRS-R) from randomization to 48 weeks in the RESCUE-ALS Trial OLE follow-upMultiple sclerosis (MS): Significant improvements in MS clinical outcomes including the visual system and global neurological function on top of immunomodulatory background standard-of-care in the VISIONARY-MS trial; significant paraclinical MRI and visual evoked potential (VEP) improvements reinforce clinical benefits:CNM-Au8 significantly improved information signaling from the eye to the...

Alamos Gold Announces Appointment of Greg Fisher as Chief Financial Officer

Written by Customer Service on March 13, 2023. Posted in Public Companies.

TORONTO, March 13, 2023 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that Greg Fisher, Senior Vice President of Finance has been promoted to Chief Financial Officer effective May 1, 2023. Greg will succeed Jamie Porter who will be leaving Alamos to pursue another opportunity in the mining industry. Jamie will continue in his current capacity and help support the transition until April 28, 2023. Greg Fisher has more than 20 years of progressive experience in the mining sector, including 13 years at Alamos Gold. Greg joined Alamos in 2010 and was appointed Vice President of Finance in 2011 and Senior Vice President of Finance in 2021. During this time, he has led the finance team and has had responsibility for regulatory financial reporting, treasury management, budgeting and...

Day: March 13, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice